Positive Phase 2 and Mechanism-of-Action Data for BOLD-100 Presented at 2024 'Metals in Medicine' Conference

VANCOUVER, BC, June 24, 2024 -- Bold Therapeutics, a company in the clinical stage of developing metallotherapeutics, has been invited to present at the 2024 'Metals in Medicine' Gordon Research Conference (GRC) held in Andover, New Hampshire from June 23 to 28, 2024. The conference, themed "Fostering Collaborations to Diagnose and Treat Diseases with Metal-Based Agents," gathers global speakers and experts to discuss the latest advancements in using metal-based agents to combat infectious diseases and cancer.

Mark Bazett, PhD, the Senior Director of Preclinical Development at Bold Therapeutics, delivered a presentation on June 24 in the session titled "Clinical Advances for Metals in Medicine." His talk, "Clinical Development of BOLD-100, a Ruthenium-Based Therapeutic Currently in Phase 2 Studies for the Treatment of Advanced Gastrointestinal Cancers," highlighted positive Phase 2 clinical outcomes for BOLD-100 in treating colorectal, biliary tract, and gastric cancers. Dr. Bazett also provided updates on Bold Therapeutics' innovative metallotherapeutic screening program and the company’s development strategy. Additionally, Shane Harrypersad, PhD, a Senior Scientist specializing in Chemistry, Manufacturing, and Controls (CMC), represented Bold Therapeutics at the conference.

Dr. Bazett remarked, "Following the announcement of strongly positive Phase 2 results at the 2024 ASCO and ASCO GI Annual Meetings earlier this year, Bold Therapeutics' BOLD-100 is now the most advanced novel metallotherapeutic in development." He emphasized that the 'Metals in Medicine' conference offers an excellent platform for Bold Therapeutics to enhance existing academic collaborations and explore new collaborative opportunities and potential metallotherapeutic candidates from leading research labs worldwide. Besides presenting, Bold Therapeutics will engage with academic experts and influential figures in the field of metallotherapeutics.

Yasmin Borutzki, BSc. MSc., a graduate student in the Meier-Menches Lab at the University of Vienna and a close collaborator of Bold Therapeutics, presented a poster on translational research related to BOLD-100 titled "Of Mice and Men: Reverse Translation Investigation of BOLD-100's Mechanism-of-Action."

Bold Therapeutics is advancing its efforts to push the boundaries of metallotherapeutics, with BOLD-100 leading the way as a promising treatment for advanced gastrointestinal cancers. The participation of Bold Therapeutics at the 2024 'Metals in Medicine' GRC underscores its commitment to fostering collaborations and driving forward the clinical development of innovative metal-based therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!